RxDoctor Payments Data

Christina Pech, PA

Physician Assistant · Camarillo, CANPI 1265816110

Payments from drug & device makers

$1,022in general payments, 2019–2025

Across 20 payments — averaging $51.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$411
  • GSK$224
  • Biogen$120
  • Boehringer Ingelheim$114
  • Verona Pharma, Inc.$47
  • AstraZeneca$43
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$1,022100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,022 in reported general payments places this provider in the 70th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$1,135
Medicare patients
61
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$45,109
TrulicityDulaglutide21$33,638
FarxigaDapagliflozin Propanediol21$28,055
JanuviaSitagliptin Phosphate25$24,617
TradjentaLinagliptin15$10,653
Atorvastatin Calcium218$1,314
Metformin Hcl178$867
Losartan Potassium90$655
Lisinopril156$643
Albuterol Sulfate HfaAlbuterol Sulfate14$598
Levothyroxine Sodium74$576
Gabapentin36$517
Pravastatin Sodium22$420
Metoprolol Succinate34$403
Ketoconazole16$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$114$55,76264 claims
Lilly USA, LLCTrulicity$14$33,63821 claims
AstraZenecaFarxiga$43$28,05521 claims
MerckJanuvia$21$24,61725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Camarillo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →